Arexvy
Payments companies reported to CMS as associated with Arexvy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Arexvy, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Arexvy
These are the largest totals companies reported as associated with Arexvy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vishal Patel | Royal Oak, MI | Sleep Medicine (Internal Medicine) | $220,915.77 |
| Jacqueline Eghrari-Sabet | Vienna, VA | Allergy & Immunology | $220,675.60 |
| Robert Sussman | Summit, NJ | $195,747.13 | |
| Todd Ellerin | Boston, MA | Infectious Disease | $181,311.64 |
| Michael Ott | Eglin Afb, FL | Pulmonary Disease | $172,156.23 |
| William Frazier | Canton, MS | Pulmonary Disease | $171,410.62 |
| Antonio Anzueto | San Antonio, TX | Pulmonary Disease | $168,619.46 |
| Steven Davidoff | Plano, TX | Critical Care Medicine (Internal Medicine) | $158,738.74 |
| Robert Feldman | Laguna Hills, CA | Geriatric Medicine (Internal Medicine) | $156,767.46 |
| Joseph Boscia | Spartanburg, SC | Pulmonary Disease | $150,884.18 |
Prescribed Arexvy?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.